Dr. Chan specializes in the surgical and medical treatment of ovarian and other pelvic cancers at CPMC. He is board certified in gynecologic oncology, and obstetrics and gynecology. He is investigating new treatments for gynecologic cancers, including targeted biologic therapies, and exploring the role of tumor-initiating cells in ovarian cancer. A clinician and surgeon, Dr. Chan is a principal investigator of studies assessing the treatment and health outcomes of ovarian and uterine cancer patients.
Sutter Health Research Enterprise
1501 Trousdale Drive
Burlingame, CA, 94010
(415) 751-1847
ChanJK@Sutterhealth.org
Primary Research Interests
Related Clinical Trials
Locally Advanced or Metastatic (NRG GY023) Temporarily on Hold
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents
Investigator: John Chung-Kai Chan M.D.
Status: Active, Not Recruiting
Metastatic (Sutro STRO-002-GM1)
Study of STRO-002, an Anti-Folate Receptor Alpha (FolRa) Antibody Drug Conjugate in Ovarian & Endometrial Cancers
Investigators: John Chung-Kai Chan M.D., Lejla Delic MD, Karolina Harger N.P.
Status: Active, Recruiting
OPAL Cohort C
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer (OPAL)
Investigator: John Chung-Kai Chan M.D.
Status: Active, Recruiting
Rosella
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
Investigator: John Chung-Kai Chan M.D.
Status: Active, Recruiting